MRKR Announces Price Target of $6 Cantor Fitzge
Post# of 35205
![](/assets/46931549/no_avatar_available_thumb.jpg)
Cantor Fitzgerald Initiates Coverage On Marker Therapeutics with Overweight Rating, Announces Price Target of $6
8:26 am ET March 19, 2021 (Benzinga) Print
Cantor Fitzgerald analyst Kristen Kluska initiates coverage on Marker Therapeutics (NASDAQ:MRKR) with a Overweight rating and announces Price Target of $6.
Latest Ratings for MRKR DateFirmActionFromTo
Mar 2021Cantor FitzgeraldInitiates Coverage OnOverweight Mar 2021Cantor FitzgeraldInitiates Coverage OnOverweight May 2020Piper SandlerDowngradesOverweightNeutral
View More Analyst Ratings for MRKR
View the Latest Analyst Ratings
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)